Structure Therapeutics @StructureTx

We were honored to team up with @SFUnified to help local students get ready for the new school year. Through this effort, our team helped provide 200 students with essential school supplies they need to thrive in the classroom. It’s a small gesture with a big impact, and we’re…

keyboard_arrow_left Previous keyboard_arrow_right Next

Today, we reported financial results for the second quarter ended June 30, 2025, and provided a business update. Top highlights include: ➡️ Topline data from oral small molecule GLP-1 RA aleniglipron Phase 2b ACCESS and ACCESS II studies on track for year-end 2025 readouts ➡️…

Today on #NationalInternDay, we're celebrating the incredible contributions of our interns in both South San Francisco and Shanghai as part of Structure’s Global Internship Program. This program is designed to give students meaningful, hands-on experience applying their studies…

keyboard_arrow_left Previous keyboard_arrow_right Next

We were proud to attend the @ObesityAction's Your Weight Matters Convention, an inspiring event including patients, advocates, clinicians, and organizations all working toward a healthier, more inclusive future for individuals living with #obesity. Being part of this event…

keyboard_arrow_left Previous keyboard_arrow_right Next

We’re back from an inspiring few days at #ADASciSessions, where the energy around innovation in the obesity field was truly remarkable. It was a milestone moment for Structure as we debuted our first-ever medical booth and shared exciting preclinical data from our oral…

keyboard_arrow_left Previous keyboard_arrow_right Next

We’re at #ADASciSessions! Among the data we're presenting is new preclinical data related to ACCG-2671, our #smallmolecule amylin receptor agonist for #obesity, expected to enter clinical development this year. Visit us at our booth to learn more, and read the details here:…

We’re participating in the Jefferies and Goldman Sachs Global Healthcare Investor Conferences in June. Read the details below and here to access the live and archived presentation webcasts: ir.structuretx.com/news-releases/…

Today, on #ClinicalTrialsDay, we recognize the individuals who participate in clinical research and the investigators, coordinators and teams who help us bring new medicines to life. At Structure, we’re focused on transforming drug development through oral #smallmolecule…

Today, we reported financial results for the first quarter ended March 31, 2025, and provided a business update. See the highlights below and read full announcement here: ir.structuretx.com/news-releases/… ➡️ Topline data from oral small molecule aleniglipron (GSBR-1290) Phase 2b ACCESS and…

2025 is the year of the oral #smallmolecule which we believe is the best solution for long term, impactful weight loss for patients living with #obesity. Our CEO Raymond Stevens joined @MelissaLeeCNBC, host of @CNBCFastMoney, and others at the roundtable to discuss the importance…

In celebration of #WomensHistoryMonth, meet Tracy Fajardo, Structure's senior manager of patient recruitment and retention and a key player of the Healthcare Businesswomen’s Association (HBA). Tracy is not only dedicated to improving patient experiences in clinical trials but…

In honor of #InternationalWomensDay, our team in Shanghai welcomed a psychology expert to explore the importance of mindfulness, stress management, and self-care, followed by a meditation and yoga session. In addition, our team in South San Francisco participated in a series of…

keyboard_arrow_left Previous keyboard_arrow_right Next

During yesterday's #WorldObesityDay, we had the privilege of hosting @ObesityAction board member Elizabeth Paul at our office in South San Francisco. Liz advocates for body positivity, standing up against bias, and promoting care and respect from health professionals and more.…

Today is #WorldObesityDay, a time to raise awareness, and advocate for better care and solutions for those living with #obesity, which affects hundreds of millions worldwide. We're advancing oral #smallmolecule medicines designed for the treatment of obesity with a goal of…

We're proud to sponsor @BeyondType1's “Let’s Talk Clinical Trials” campaign, aimed at educating the #diabetes community on clinical trials through a variety of educational resources. Check out the article below which debunks common myths about clinical trials.

Beyond Type 1 @BeyondType1

6 months ago

We're proud to sponsor @BeyondType1's “Let’s Talk Clinical Trials” campaign, aimed at educating the #diabetes community on clinical trials through a variety of educational resources. Check out the article below which debunks common myths about clinical trials.

0 0 0 813 0

Today, we reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update. Read the top highlights below and view the full announcement here: ir.structuretx.com/news-releases/… ➡️ Aleniglipron (GSBR-1290) ACCESS and ACCESS II studies…

What better way to kick off the year than by bringing the full U.S. team together to celebrate our wins and set the stage for another year of growth. Congratulations to the recipients of our Foundation Awards. We believe strong foundations make bold visions possible. We…

keyboard_arrow_left Previous keyboard_arrow_right Next

In honor of International Day of Women and Girls in Science, we are pleased to introduce our Women’s Leadership Network, Structure’s global internal organization dedicated to women’s empowerment, leadership and excellence. Hear from our founding members below on why we believe…

We have launched our new website! This transformation is more than a new look—it's a reaffirmation of our mission, our passion, and our relentless drive to make medicines more accessible to all. Patients are waiting for treatment options that are available, cost effective, and…